JP2004530657A - 上皮組織にわたるおよび上皮組織への薬物送達を増強するための組成物および方法 - Google Patents

上皮組織にわたるおよび上皮組織への薬物送達を増強するための組成物および方法 Download PDF

Info

Publication number
JP2004530657A
JP2004530657A JP2002569108A JP2002569108A JP2004530657A JP 2004530657 A JP2004530657 A JP 2004530657A JP 2002569108 A JP2002569108 A JP 2002569108A JP 2002569108 A JP2002569108 A JP 2002569108A JP 2004530657 A JP2004530657 A JP 2004530657A
Authority
JP
Japan
Prior art keywords
delivery
conjugate
arginine
transporter
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002569108A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004530657A5 (enExample
Inventor
ジョナサン ビー． ロスバード，
ポール エイ． ウェンダー，
ピー． レオ マックグレーン，
ラリサ ブイ． エス． シスタ，
ソーステン エイ． カーシュバーグ，
Original Assignee
セルゲイト， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セルゲイト， インコーポレイテッド filed Critical セルゲイト， インコーポレイテッド
Publication of JP2004530657A publication Critical patent/JP2004530657A/ja
Publication of JP2004530657A5 publication Critical patent/JP2004530657A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/146—Peptides, e.g. proteins the peptide being a polyamino acid, e.g. poly-lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nanotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
JP2002569108A 2001-02-23 2002-02-25 上皮組織にわたるおよび上皮組織への薬物送達を増強するための組成物および方法 Pending JP2004530657A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/792,480 US6669951B2 (en) 1999-08-24 2001-02-23 Compositions and methods for enhancing drug delivery across and into epithelial tissues
PCT/US2002/005829 WO2002069930A1 (en) 2001-02-23 2002-02-25 Compositions and methods for enhancing drug delivery across and into epithelial tissues

Publications (2)

Publication Number Publication Date
JP2004530657A true JP2004530657A (ja) 2004-10-07
JP2004530657A5 JP2004530657A5 (enExample) 2005-12-22

Family

ID=25157022

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002569108A Pending JP2004530657A (ja) 2001-02-23 2002-02-25 上皮組織にわたるおよび上皮組織への薬物送達を増強するための組成物および方法
JP2002567285A Pending JP2004533414A (ja) 2001-02-23 2002-02-25 眼組織を横切る薬物送達および眼組織内への薬物送達を増強するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2002567285A Pending JP2004533414A (ja) 2001-02-23 2002-02-25 眼組織を横切る薬物送達および眼組織内への薬物送達を増強するための組成物および方法

Country Status (6)

Country Link
US (5) US6669951B2 (enExample)
EP (2) EP1372626A4 (enExample)
JP (2) JP2004530657A (enExample)
CA (2) CA2438326A1 (enExample)
MX (2) MXPA03007590A (enExample)
WO (2) WO2002067917A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010514781A (ja) * 2006-12-29 2010-05-06 ルバンス セラピュティックス インク． Ｈｉｖ−ｔａｔに由来するポリペプチド断片を用いて安定化されるボツリヌス毒素を局所適用及び経皮送達する組成物及び方法
JP2014522816A (ja) * 2011-06-22 2014-09-08 ビョーメ バイオサイエンシズ ピーブイティー．リミテッド コンジュゲートベースの抗真菌性および抗菌性プロドラッグ
WO2019198316A1 (ja) * 2018-04-09 2019-10-17 国立研究開発法人産業技術総合研究所 生理活性を持つ中分子の薬物動態を改善する方法、薬物動態の改善を利用した中分子ライブラリの製造法
JP2020519622A (ja) * 2017-05-11 2020-07-02 ケアジェン カンパニー, リミテッドCaregen Co., Ltd. イソトレチノインとペプチドの結合体

Families Citing this family (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135191B2 (en) * 1997-09-04 2006-11-14 Zsolt Istvan Hertelendy Urogenital or anorectal transmucosal vaccine delivery system
ES2260916T3 (es) * 1998-07-08 2006-11-01 Kirin-Amgen, Inc. Preparacion en polvo para administracion a traves de la mucosa que contiene una medicina polimerica.
US20060025387A1 (en) * 1998-12-23 2006-02-02 Cytoscan Sciences Llc Compositions and methods for the treatment of disorders of the central and peripheral nervous systems
US7214711B2 (en) * 1998-12-23 2007-05-08 Neurotherapeutics Pharma Llc Method of treating migraine headache without aura
US8008283B2 (en) * 1998-12-23 2011-08-30 Neurotherapeutics Pharma, Inc. Methods and compositions for the treatment of neuropsychiatric disorders
US8722668B2 (en) 1998-12-23 2014-05-13 Daryl W. Hochman Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders
US6669951B2 (en) * 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US7229961B2 (en) * 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
DK1301213T3 (en) * 2000-07-21 2017-03-27 Revance Therapeutics Inc MULTI-COMPONENT SYSTEMS FOR BIOLOGICAL TRANSPORT
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
AUPR549901A0 (en) * 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
US20040097472A1 (en) * 2000-11-14 2004-05-20 West Simon Michael Complexes of phosphate derivatives
DE60233137D1 (de) * 2001-02-16 2009-09-10 Univ R Transporter mit beabstandeten arginin-teilchen
EP1391209A4 (en) * 2001-05-30 2009-12-16 Chugai Pharmaceutical Co Ltd PROTEIN PREPARATION
MXPA04000654A (es) 2001-07-27 2004-03-19 Vital Health Sciences Pty Ltd Terapia dermica usando derivados de fosfato de agente de transferencia de electrones.
MXPA04005611A (es) * 2001-12-11 2005-04-19 Cellgate Inc Reactivos y conjugados de transporte de guanidinio.
WO2003049774A1 (en) * 2001-12-13 2003-06-19 Vital Health Sciences Pty Ltd Transdermal transport of compounds
US7482018B2 (en) 2001-12-21 2009-01-27 Soane Family Trust Use of oligomers and polymers for drug solubilization, stabilization, and delivery
FR2836474B1 (fr) * 2002-02-22 2004-12-24 Synt Em Composes, compositions et methode pour le transport des molecules de cyclosporine a travers la barriere hemato-encephalique
WO2003090604A2 (en) * 2002-04-24 2003-11-06 University Of Florida Method of endovascular brain mapping
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
EP1562627A4 (en) * 2002-08-23 2006-11-02 Mclean Hospital Corp CORTICOSTEROID CONJUGATES AND ITS USES
WO2004032963A2 (en) * 2002-10-04 2004-04-22 Photokinetix Inc. Photokinetic delivery of biologically active substances using pulsed incoherent light
US6969514B2 (en) * 2003-02-05 2005-11-29 Soll David B Method for treating elevated intraocular pressure, including glaucoma
CA2518265A1 (en) * 2003-03-17 2004-09-30 Albany Molecular Research, Inc. Novel cyclosporins
US7332164B2 (en) * 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
AU2004235396B2 (en) * 2003-04-29 2010-11-25 Sarepta Therapeutics, Inc. Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells
EP3167935B1 (en) * 2003-05-01 2018-07-18 Cornell Research Foundation, Inc. Method and carrier complexes for delivering molecules to cells
WO2005013905A2 (en) * 2003-08-07 2005-02-17 Avi Biopharma, Inc. SENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING ssRNA VIRAL INFECTION
US20050136437A1 (en) * 2003-08-25 2005-06-23 Nastech Pharmaceutical Company Inc. Nanoparticles for delivery of nucleic acids and stable double-stranded RNA
US20050148534A1 (en) * 2003-09-22 2005-07-07 Castellino Angelo J. Small molecule compositions and methods for increasing drug efficiency using compositions thereof
US20050222068A1 (en) * 2003-10-23 2005-10-06 Mourich Dan V Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells
US20050203041A1 (en) * 2003-09-23 2005-09-15 Mourich Dan V. Antisense compound and method for selectively killing activated T cells
US20050074506A1 (en) * 2003-10-02 2005-04-07 Brainsgate Ltd. Targeted release of nitric oxide in the CNS circulation for modulating the BBB and treating disorders
DE10355559A1 (de) * 2003-11-21 2005-06-23 Orthogen Ag Transskin
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
JP2007526316A (ja) * 2004-03-01 2007-09-13 ルーメン セラピューティックス リミテッド ライアビリティ カンパニー 疾患を処置するための組成物および方法
RU2477136C2 (ru) * 2004-03-03 2013-03-10 Вайтал Хэлф Сайнсис Пти Лтд Алкалоидные составы
BRPI0508440A (pt) 2004-03-03 2007-07-24 Revance Therapeutics Inc composições e métodos para diagnóstico tópico e transporte terapêutico
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
HUE025656T2 (en) 2004-03-03 2016-04-28 Revance Therapeutics Inc Topical application and transdermal delivery of botulinum toxins
EP1734991A4 (en) * 2004-04-14 2012-10-24 Avirid Inc COMPOSITIONS COMPRISING MODIFIED NUCLEASES DIRECTED AGAINST VIRAL NUCLEIC ACIDS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF VIRAL DISEASES
US20050288246A1 (en) 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
KR100862930B1 (ko) 2004-06-23 2008-10-13 시리온 테라퓨틱스, 인크. 레티닐 유도체를 사용하여 안 증상을 치료하기 위한 방법및 조성물
WO2006012692A1 (en) * 2004-08-03 2006-02-09 Vital Health Sciences Pty Ltd Carrier for enteral administration
US8129352B2 (en) 2004-09-16 2012-03-06 Avi Biopharma, Inc. Antisense antiviral compound and method for treating ssRNA viral infection
JP2008514702A (ja) * 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド 新規シクロスポリン類似体およびそれらの薬学的使用
US7378391B2 (en) * 2004-09-29 2008-05-27 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
WO2006041631A2 (en) * 2004-10-06 2006-04-20 Amr Technology, Inc. Novel cyclosporin alkynes and their utility as pharmaceutical agents
US7442682B2 (en) * 2004-10-19 2008-10-28 Nitto Denko Corporation Transepithelial delivery of peptides with incretin hormone activities
US8357664B2 (en) 2004-10-26 2013-01-22 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
US7524829B2 (en) * 2004-11-01 2009-04-28 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
WO2006052860A2 (en) 2004-11-04 2006-05-18 Sirion Therapeutics, Inc. Modulators of retinol-retinol binding protein (rbp)-transthyretin (ttr) complex formation
EP1656951A1 (en) * 2004-11-12 2006-05-17 Xigen S.A. Conjugates with enhanced cell uptake activity
US7603097B2 (en) 2004-12-30 2009-10-13 Valeo Radar Systems, Inc. Vehicle radar sensor assembly
WO2006086667A2 (en) 2005-02-09 2006-08-17 Avi Bio Pharma, Inc. Antisense composition and method for treating muscle atrophy
US20090239827A1 (en) * 2005-03-03 2009-09-24 Esra Ogru Compounds having lipid lowering properties
KR20070110402A (ko) 2005-03-03 2007-11-16 레반스 테라퓨틱스 보툴리눔 독소의 국소 적용 및 경피 전달을 위한 조성물 및방법
ES2362301T3 (es) 2005-03-03 2011-07-01 Revance Therapeutics, Inc. Composiciones y procedimientos para aplicaciones tópicas y liberación transdérmica de un oligopéptido.
US20060240032A1 (en) * 2005-03-31 2006-10-26 Hinrichs David J Immunomodulating compositions and methods for use in the treatment of human autoimmune diseases
US9168216B2 (en) 2005-06-17 2015-10-27 Vital Health Sciences Pty. Ltd. Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
AU2006287530A1 (en) * 2005-09-08 2007-03-15 Sarepta Therapeutics, Inc. Antisense antiviral compound and method for treating picornavirus infection
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
JP5122460B2 (ja) * 2005-09-16 2013-01-16 アラーガン、インコーポレイテッド 治療薬の眼内輸送のための組成物および方法
WO2007038172A2 (en) * 2005-09-23 2007-04-05 Nitto Denko Corporation Guanidinium carriers
WO2007038169A2 (en) 2005-09-23 2007-04-05 Nitto Denko Corporation Multi-valent guanidinium compounds for molecular translocation across cellular membranes and epithelial tissues
US7700565B2 (en) 2005-09-23 2010-04-20 Nitto Denko Corporation Peptide nucleic acid based guanidinium compounds
US20070149526A1 (en) * 2005-10-17 2007-06-28 Neurotherapeutics Pharma, L.L.C. Diuretic and diuretic-like compound analogs
US8501704B2 (en) * 2005-11-08 2013-08-06 Sarepta Therapeutics, Inc. Immunosuppression compound and treatment method
WO2007059528A2 (en) 2005-11-17 2007-05-24 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
US7740880B2 (en) 2006-03-03 2010-06-22 University Of Utah Research Foundation Polymeric carrier for delivery of small interfering RNA
US7696165B2 (en) * 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7696166B2 (en) * 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US8785407B2 (en) * 2006-05-10 2014-07-22 Sarepta Therapeutics, Inc. Antisense antiviral agent and method for treating ssRNA viral infection
US20090311699A1 (en) * 2006-09-25 2009-12-17 Cmed Technologies Ltd. Method of surface plasmon resonance (spr) to detect genomic aberrations in patients with chronic lymphocytic leukemia
EP2561891A3 (en) * 2006-09-27 2013-03-06 Paolo Botti Means and methods of enhancing delivery to biological systems
EP2091914A4 (en) 2006-11-08 2010-12-29 Chongxi Yu TRANSDERMAL ADMINISTRATION SYSTEMS FOR PEPTIDES AND RELATED CONNECTIONS
NZ598159A (en) * 2006-12-29 2013-08-30 Revance Therapeutics Inc Transport molecules using reverse sequence hiv-tat polypeptides
ATE534737T1 (de) * 2007-01-26 2011-12-15 Iucf Hyu Gezielte abgabe von sirna
WO2008100560A2 (en) * 2007-02-14 2008-08-21 University Of Southern California Estrogen receptor modulators, associated pharmaceutical compositions and methods of use
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
CA2691673A1 (en) * 2007-06-29 2009-01-08 Avi Biopharma, Inc. Tissue specific peptide conjugates and methods
AU2015200600B2 (en) * 2007-06-29 2017-04-20 Sarepta Therapeutics, Inc. Tissue specific peptide conjugates and methods
DK2178549T3 (en) 2007-07-26 2017-01-09 Revance Therapeutics Inc Antimicrobial peptide AND COMPOSITIONS THEREOF
WO2009032148A1 (en) * 2007-08-29 2009-03-12 Tufts University Methods of making and using a cell penetrating peptide for enhanced delivery of nucleic acids, proteins, drugs, and adenovirus to tissues and cells, and compositions and kits
US20110160146A1 (en) * 2008-02-07 2011-06-30 National Institute of Health (NIH) Conjungation of Small Molecules to Octaarginine Transporters for Overcoming Multi-Drug Resistance
EP2123262A1 (en) 2008-05-20 2009-11-25 Consorzio per il Centro di Biomedica Moleculare Scrl Polyelectrolyte-encapsulated gold nanoparticles capable of crossing blood-brain barrier
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
EP2480210A4 (en) * 2008-09-23 2016-07-13 Lab Skin Care Inc ACTUATED UNIFORMS, RIGID, SPHERICAL NANOPOROUS CALCIUMOPHOSPHATE PARTICLES AND METHOD FOR THEIR USE AND MANUFACTURE
US8592386B2 (en) * 2008-12-17 2013-11-26 Sarepta Therapeutics, Inc. Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
EP2660247A3 (en) * 2009-05-08 2014-09-03 Chongxi Yu High penetration prodrug compositions of peptides and peptide-related compounds
EP2437772B1 (en) 2009-06-05 2017-12-06 13Therapeutics, Inc. Immunoregulatory peptides and methods of use
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
AU2010319314C1 (en) 2009-11-13 2016-09-01 Sarepta Therapeutics, Inc. Antisense antiviral compound and method for treating influenza viral infection
NO2504357T3 (enExample) 2009-11-23 2017-12-30
WO2011094814A1 (en) 2010-02-05 2011-08-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
CA2794734C (en) 2010-03-30 2017-12-12 Phosphagenics Limited Transdermal delivery patch
CA2797093C (en) 2010-04-26 2019-10-29 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
CA2797362C (en) 2010-04-27 2020-12-08 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
WO2011139853A2 (en) 2010-04-28 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
EP2563383B1 (en) 2010-04-29 2017-03-01 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
US8986680B2 (en) 2010-04-29 2015-03-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
CA2797977C (en) 2010-05-03 2019-08-20 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
CN103140233B (zh) 2010-05-03 2017-04-05 Atyr 医药公司 与甲硫氨酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现
WO2011139986A2 (en) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
EP2566499B1 (en) 2010-05-04 2017-01-25 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
CA2799197C (en) 2010-05-14 2019-10-29 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
AU2011258106B2 (en) 2010-05-27 2017-02-23 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
CN103118694B (zh) 2010-06-01 2016-08-03 Atyr医药公司 与赖氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
JP6116479B2 (ja) 2010-07-12 2017-04-19 エータイアー ファーマ， インコーポレイテッド グリシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
US8198429B2 (en) 2010-08-09 2012-06-12 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
JP5964304B2 (ja) 2010-08-25 2016-08-03 エータイアー ファーマ， インコーポレイテッド チロシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
WO2012050673A1 (en) * 2010-10-14 2012-04-19 Wisconsin Alumni Research Foundation Methods for the treatment of x-linked hypophosphatemia and related disorders
AU2010362444B2 (en) 2010-10-14 2015-08-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2012122586A1 (en) 2011-03-15 2012-09-20 Phosphagenics Limited New composition
US8580748B2 (en) 2011-04-06 2013-11-12 13Therapeutics, Inc. Peptides for the treatment of hearing
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
HK1207562A1 (en) * 2012-01-18 2016-02-05 苏州泰飞尔医药有限公司 High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions
US9816066B2 (en) 2012-04-24 2017-11-14 The Regents Of The University Of California Method for delivery of small molecules and proteins across the cell wall of algae using molecular transporters
WO2013184614A2 (en) * 2012-06-04 2013-12-12 Indiana University Research And Technology Corporation Peptide conjugates for treating pain
US9089536B2 (en) 2012-06-06 2015-07-28 Brian J. Smith Ophthalmic solution for absorbing ultraviolet radiation and method for absorbing ultraviolet radiation
EA201590622A1 (ru) * 2012-10-16 2015-10-30 Эндосайт, Инк. Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения
WO2014066916A2 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
US10172789B2 (en) 2013-01-24 2019-01-08 Palvella Therapeutics Llc Compositions for transdermal delivery of mTOR inhibitors
AU2014310360B2 (en) * 2013-06-11 2019-10-24 PPL (BVI) Limited Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
EA201501080A1 (ru) 2013-06-26 2016-07-29 Ксижен Инфлемейшн Лтд. Новое применение обладающих способностью проникать в клетку пептидных ингибиторов пути трансдукции сигнала jnk для лечения различных заболеваний
JP2016538327A (ja) 2013-09-24 2016-12-08 ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション デスモグレイン２（ｄｓｇ２）結合タンパク質およびその使用
PT3149025T (pt) 2014-05-21 2019-08-01 Entrada Therapeutics Inc Peptídeos penetrantes de células e métodos de fabrico e utilização dos mesmos
US10815276B2 (en) 2014-05-21 2020-10-27 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
WO2016033368A1 (en) 2014-08-27 2016-03-03 Ohio State Innovation Foundation Improved peptidyl calcineurin inhibitors
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
US11020417B2 (en) 2015-06-04 2021-06-01 Sarepta Therapeutics, Inc Methods and compounds for treatment of lymphocyte-related diseases and conditions
US10973761B2 (en) 2015-12-09 2021-04-13 Phosphagenics Limited Pharmaceutical formulation
JP7179715B2 (ja) 2016-07-27 2022-11-29 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 核酸送達用の崩壊性細胞透過性複合体
NZ755416A (en) 2016-12-19 2023-05-26 Sarepta Therapeutics Inc Exon skipping oligomer conjugates for muscular dystrophy
JP7198754B2 (ja) 2016-12-21 2023-01-04 アベーチョ バイオテクノロジー リミテッド 方法
WO2018129364A1 (en) 2017-01-06 2018-07-12 Palvella Therapeutics Llc Anhydrous compositions of mtor inhibitors and methods of use
EP4324460A3 (en) 2017-09-15 2024-04-24 Dyve Biosciences, Inc. Sodium bicarbonate for use in the treatment of gout and related disorders
US11339192B2 (en) 2017-10-04 2022-05-24 Ohio State Innovation Foundation Bicyclic peptidyl inhibitors
US11576946B2 (en) 2018-01-29 2023-02-14 Ohio State Innovation Foundation Peptidyl inhibitors of calcineurin-NFAT interaction
EP3746105A4 (en) 2018-01-29 2022-05-18 Ohio State Innovation Foundation CYCLIC PEPTIDYLIN HIBITORS OF THE CAL-PDZ-BINDING DOMAIN
WO2019165183A1 (en) 2018-02-22 2019-08-29 Entrada Therapeutics, Inc. Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
EP3787671A4 (en) 2018-05-04 2022-06-15 Ohio State Innovation Foundation NON-PEPTIDE CELL-PENETRATING MOTIFS
WO2019217682A1 (en) 2018-05-09 2019-11-14 Ohio State Innovation Foundation Cyclic cell-penetrating peptides with one or more hydrophobic residues
KR102167755B1 (ko) 2018-05-23 2020-10-19 주식회사 큐어바이오 단편화된 grs 폴리펩타이드, 이의 변이체 및 이들의 용도
EP3817743A4 (en) 2018-07-02 2022-07-06 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE
HUE062848T2 (hu) 2018-09-14 2023-12-28 Enlitisa Shanghai Pharmaceutical Co Ltd Montelukaszt és peptidek konjugátumai
CN109010798A (zh) * 2018-09-17 2018-12-18 中山大学中山眼科中心 一种多肽的新用途
WO2020117429A1 (en) * 2018-12-04 2020-06-11 Purdue Research Foundation Novel antibacterial cell-penetrating peptides
US20220215930A1 (en) * 2019-05-12 2022-07-07 Makesense Digital Health Technologies Ltd. A system and a method for heal th and diet management and nutritional monitoring
WO2021072112A1 (en) 2019-10-09 2021-04-15 Hdt Bio Corp. Detection of desmoglein-2 in cancers of epithelial origin
US20210346506A1 (en) * 2020-05-07 2021-11-11 Guibai Liang Prodrug of itraconazole and uses thereof
WO2024100552A1 (en) * 2022-11-08 2024-05-16 Alcon Inc. Prodrugs and compositions for ophthalmology applications

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE744988C (de) 1941-02-01 1944-02-22 Wilhelm Ulrich O Handschraem- und Schlitzsaege
GB744988A (en) 1952-01-31 1956-02-15 Allen & Hanburys Ltd Improvements in preparations of insulin
GB1541435A (en) 1975-02-04 1979-02-28 Searle & Co Immunological materials
US4701521A (en) 1978-07-17 1987-10-20 The Trustees Of Boston University Method of effecting cellular uptake of molecules
WO1979000515A1 (en) 1978-01-16 1979-08-09 Univ Boston Method of effecting cellular uptake of molecules
US4847240A (en) 1978-01-16 1989-07-11 The Trustees Of Boston University Method of effecting cellular uptake of molecules
US4631190A (en) 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US4880911A (en) 1982-03-19 1989-11-14 G. D. Searle & Co. Fused polypeptides and methods for their detection
US4532207A (en) 1982-03-19 1985-07-30 G. D. Searle & Co. Process for the preparation of polypeptides utilizing a charged amino acid polymer and exopeptidase
JPH0236570B2 (ja) 1985-05-30 1990-08-17 Toko Yakuhin Kogyo Kk Shoenchintsunankozai
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5162505A (en) 1989-09-19 1992-11-10 Centocor Proteins modified with positively charged carriers and compositions prepared therefrom
US5028707A (en) 1989-11-20 1991-07-02 Board Of Regents, University Of Texas 4-hydroxyquinaldic acid derivatives
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
ES2091916T3 (es) 1989-12-21 1996-11-16 Whitehead Biomedical Inst Metodo para suministrar moleculas en el interior de celulas eucarioticas.
US5268164A (en) * 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5646120A (en) 1990-10-24 1997-07-08 Allelix Biopharmaceuticals, Inc. Peptide-based inhibitors of HIV replication
US5674849A (en) 1990-10-24 1997-10-07 Allelix Biopharmaceuticals Inc. Anti-viral compositions
DK0554284T3 (da) 1990-10-24 1997-01-06 Allelix Biopharma Peptid-baserede hæmmere af Hiv-replikation
US5633230A (en) 1990-10-24 1997-05-27 Allelix Biopharmaceuticals, Inc. Treatment of cytomegalovirus infection
US5831001A (en) 1990-10-24 1998-11-03 Allelix Biopharmaceuticals Inc. Treatment of herpesvirus infection
KR100252547B1 (ko) 1991-09-05 2000-09-01 프레드 마리얀스키 폴리-또는 올리고누클레오티드의 세포로의 표적화된 전달
JPH08501060A (ja) 1992-04-23 1996-02-06 アレリックス バイオファーマスーティカルス インコーポレーテッド ヘルペスウィルス感染症の治療
CA2094658A1 (en) 1992-04-23 1993-10-24 Martin Sumner-Smith Intracellular delivery of biochemical agents
GB9213077D0 (en) 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
EP0903408A3 (en) 1992-08-21 2005-11-02 Biogen, Inc. Tat-derived transport polypeptide
EP0599303A3 (en) 1992-11-27 1998-07-29 Takeda Chemical Industries, Ltd. Peptide conjugate
AU5829994A (en) 1992-12-22 1994-07-19 Allelix Biopharmaceuticals Inc. Synergistic compositions containing an antiviral nucleoside analogue and an antiviral oligopeptide
CA2152373C (en) 1993-10-22 1998-12-15 Michael Twist (Deceased) Treatment of cytomegalovirus infection
US6013628A (en) * 1994-02-28 2000-01-11 Regents Of The University Of Minnesota Method for treating conditions of the eye using polypeptides
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
US5716614A (en) 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
US5620013A (en) * 1994-10-21 1997-04-15 American Cyanamid Company Method for destroying residual lens epithelial cells
US5783178A (en) 1994-11-18 1998-07-21 Supratek Pharma. Inc. Polymer linked biological agents
AU4690596A (en) 1994-12-30 1996-07-24 Chiron Viagene, Inc. Nucleic acid condensing agents with reduced immunogenicity
PL189698B1 (pl) 1996-03-12 2005-09-30 Pg Txl Co Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania
AU729643B2 (en) 1996-05-01 2001-02-08 Antivirals Inc. Polypeptide conjugates for transporting substances across cell membranes
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
JP3770666B2 (ja) 1996-09-20 2006-04-26 株式会社ティ・ティ・エス技術研究所 経粘膜吸収製剤用組成物
JPH10204000A (ja) 1997-01-22 1998-08-04 Nof Corp 経皮吸収促進剤
US6228344B1 (en) 1997-03-13 2001-05-08 Mallinckrodt Inc. Method of measuring physiological function
ES2210761T3 (es) * 1997-05-21 2004-07-01 The Board Of Trustees Of The Leland Stanford Junior University Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas.
WO2001013957A2 (en) 1999-08-24 2001-03-01 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6730293B1 (en) * 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
US7229961B2 (en) * 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US20020009491A1 (en) * 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
DK1301213T3 (en) 2000-07-21 2017-03-27 Revance Therapeutics Inc MULTI-COMPONENT SYSTEMS FOR BIOLOGICAL TRANSPORT
DE60233137D1 (de) * 2001-02-16 2009-09-10 Univ R Transporter mit beabstandeten arginin-teilchen
US9810571B1 (en) 2016-12-15 2017-11-07 Chung-Hsiu Su Hand truck with a loading weighing mechanism

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010514781A (ja) * 2006-12-29 2010-05-06 ルバンス セラピュティックス インク． Ｈｉｖ−ｔａｔに由来するポリペプチド断片を用いて安定化されるボツリヌス毒素を局所適用及び経皮送達する組成物及び方法
JP2014522816A (ja) * 2011-06-22 2014-09-08 ビョーメ バイオサイエンシズ ピーブイティー．リミテッド コンジュゲートベースの抗真菌性および抗菌性プロドラッグ
JP2020519622A (ja) * 2017-05-11 2020-07-02 ケアジェン カンパニー, リミテッドCaregen Co., Ltd. イソトレチノインとペプチドの結合体
JP7016886B2 (ja) 2017-05-11 2022-02-07 ケアジェン カンパニー，リミテッド イソトレチノインとペプチドの結合体
US11351266B2 (en) 2017-05-11 2022-06-07 Caregen Co., Ltd. Conjugate of isotretinoin and peptide
US12005123B2 (en) 2017-05-11 2024-06-11 Caregen Co., Ltd. Conjugate of isotretinoin and peptide
WO2019198316A1 (ja) * 2018-04-09 2019-10-17 国立研究開発法人産業技術総合研究所 生理活性を持つ中分子の薬物動態を改善する方法、薬物動態の改善を利用した中分子ライブラリの製造法

Also Published As

Publication number Publication date
US20110206610A1 (en) 2011-08-25
US8623833B2 (en) 2014-01-07
EP1367995A1 (en) 2003-12-10
US20040186045A1 (en) 2004-09-23
WO2002069930A1 (en) 2002-09-12
EP1372626A1 (en) 2004-01-02
US20020127198A1 (en) 2002-09-12
WO2002067917A1 (en) 2002-09-06
EP1372626A4 (en) 2007-08-01
EP1367995A4 (en) 2007-08-01
MXPA03007590A (es) 2003-12-04
US6669951B2 (en) 2003-12-30
US20070173436A1 (en) 2007-07-26
JP2004533414A (ja) 2004-11-04
CA2438784A1 (en) 2002-09-06
US20140213532A1 (en) 2014-07-31
MXPA03007591A (es) 2003-12-04
CA2438326A1 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
US6669951B2 (en) Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6730293B1 (en) Compositions and methods for treating inflammatory diseases of the skin
US6593292B1 (en) Compositions and methods for enhancing drug delivery across and into epithelial tissues
US8729010B2 (en) Compositions and methods for enhancing drug delivery across and into ocular tissues
EP1401473B1 (en) Transporters comprising spaced arginine moieties
JP2003523982A (ja) 生体膜および生体組織を横切る薬物送達を増強するための、組成物および方法
AU2002306500A1 (en) Transporters comprising spaced arginine moieties
JP2004533414A5 (enExample)
AU2002303102A1 (en) Compositions and methods for enhancing drug delivery across and into epithelial tissues
HK1152869A (en) Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
AU2002245529A1 (en) Compositions and methods for enhancing drug delivery across and into ocular tissues

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081023

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090108

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090116

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090622